The gap between trailing and forward P/E implies analysts expect earnings to recover, yet revenue growth near negative 0.7 percent year over year gives limited support for that expectation. A PEG below 1.0 may appear to signal undervaluation, but this rests on earnings growth assumptions that the top line does not yet confirm. Relative to Molson Coors at 8.4 times earnings and Ambev at 15.1 times, BUD sits at a premium that investors should monitor against the durability of its gross margin advantage.

The stable gross margin suggests pricing power and procurement scale are offsetting input cost pressure, which is consistent with a durable cost advantage. The large gap between operating and net margin appears to reflect interest expense and tax drag rather than operating weakness. Investors should treat operating margin as the cleaner measure of earning power while monitoring whether financing costs continue to absorb an increasing share of operating profit.

The trend in equity and debt suggests a multi-year deleveraging effort that has largely stabilized, though absolute debt of about $72 billion remains large relative to cash. Interest coverage above 4 times provides a cushion, but a further decline in revenue could compress that headroom quickly. Refinancing exposure and currency matching of debt warrant further investigation, since the headline ratio alone does not reveal maturity structure.

A current ratio below 1.0 is typical for a business with strong negative working capital, and the consistent cash conversion cycle of roughly negative 112 days supports that interpretation. Under severe stress, however, the dependence on supplier financing and seasonal year-end inflows could become a constraint if payables tighten. Investors should monitor whether cash reserves of about $7.6 billion remain adequate against current liabilities during a demand downturn.